Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat

NCT ID: NCT03005717

Last Updated: 2017-10-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 162 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-12-22
• Study Completion Date: 2017-06-02

Brief Summary

Study LIPO-202-CL-31 is a multi center, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of two different doses of LIPO-202 versus placebo on submental bulging due to subcutaneous fat. Approximately 150 participants of either gender who have a "Moderate Bulge" or "Large Bulge" in the submental fat (on Patient-Reported Submental Bulging Scale [PR-SBS] and Clinician-Reported Submental Bulging Scale [CR-SBS]) will be recruited for this study.

Detailed Description

Potential subjects will present and complete the Screening Visit. All qualifying subjects will be randomized to one of three treatment groups and treated with up to 30 subcutaneous injections of the assigned study drug into submental fat, once a week for 8 weeks. Upon completion of treatment visits, subject will return to the clinic for a follow-up visit and end of study visit, one and four weeks after the last treatment. The number and pattern of injections will be based on the area (cm x cm) of submental fat at baseline. At each visit the subjects will also undergo an examination of the treatment area, collection of vital signs and questioning about possible adverse events (AEs).

The study consists of 11 visits: a Screening Visit, eight Treatment Visits, a Follow up Visit and an End of Study Visit.

Conditions

Submental Fat

Keywords

submental; Salmeterol Xinafoate; LIPO-202; bulge

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Active High

Drug: LIPO 202 (Salmeterol Xinafoate for Injection), 0.2 mcg SX/mL Total Weekly Dose: up to 3.0 mcg SX

Group Type: EXPERIMENTAL

LIPO-202

Intervention Type: DRUG

Active Low

Drug: LIPO 202 (Salmeterol Xinafoate for Injection), 0.02 mcg SX/mL Total Weekly Dose: up to 0.3 mcg SX

Group Type: EXPERIMENTAL

LIPO-202

Intervention Type: DRUG

Placebo

Placebo for LIPO 202 (Salmeterol Xinafoate for Injection)

Group Type: PLACEBO_COMPARATOR

Placebo for LIPO-202

Intervention Type: DRUG

Lyophile manufactured to mimic LIPO-202 lyophile.

Interventions

LIPO-202

Intervention Type: DRUG

Placebo for LIPO-202

Lyophile manufactured to mimic LIPO-202 lyophile.

Intervention Type: DRUG

Other Intervention Names

Salmeterol Xinafoate for Injection; Placebo

Eligibility Criteria

Inclusion Criteria

1. Healthy males or non-pregnant females;

2. Capable of providing written, informed consent; and ,

3. Have submental bulging that is evaluated by the Investigator as "Moderate" or "Large".

Exclusion Criteria

1. History of prior treatment to reduce submental bulging;

2. History of derm fillers, chemical peels, or laser or radio frequency procedures in the neck/chin area within 12 months of screening;

3. History of botulinum toxin in the neck/chin area within 6 months of screening;

4. Any skin conditions (including, but not limited to: skin infections, psoriasis, eczema, keloids, tattoos or hypertrophic or tethered scars) or history of trauma in the treatment area that may affect study procedures;

5. A score of 4 (Extreme Laxity) on the Skin Laxity Assessment Scale at Visit 1 (Screening);

6. Any known hypersensitivity to the study drug and/or any of the components;

7. Prior or current enrollment in any Lithera/Neothetics sponsored LIPO-102/LIPO-202 study;

8. Concurrently enrolled in another investigational drug or device study or used any experimental or investigational drug or device within 30 days of screening;

9. Female subject who is pregnant or lactating;

10. Any medical condition that in the opinion of the Investigator might complicate study procedures or assessments or jeopardize the subject's safety, including, but not limited to:

1. any bleeding or connective tissue disorders;

2. any clinically significant kidney or liver disease;

3. any untreated thyroid disease;

4. asthma, COPD, diabetes (Type I and II) or cardiovascular disease

5. history of major surgery within 30 days prior to randomization, or planned surgery during the study period;

11. Used drugs with anticoagulant activity (including aspirin) within 14 days prior to randomization, β adrenergic receptor agonists or blockers, strong CYP3A inhibitors, or nonpotassium sparing diuretics (e.g., loop or thiazide diuretics) within 28 days prior to randomization;

12. Used tricyclic antidepressants or monoamine oxidase inhibitor medications within 14 days prior to randomization;

13. Unlikely or unable to adhere to the study visit schedule or comply with protocol procedures.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Neothetics, Inc

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Daniel Piacquadio, MD

Role: STUDY_CHAIR

Consultant, Therapeutics, Inc.

Locations

Clinical Testing of Beverly Hills

Beverly Hills, California, United States

Ablon Skin Institute And Research Center

Manhattan Beach, California, United States

AboutSkin Research

Greenwood Village, Colorado, United States

Skin Research Institute

Coral Gables, Florida, United States

Grekin Skin Institute

Warren, Michigan, United States

Minnesota Clinical Study Center

Fridley, Minnesota, United States

Mercy Research

Washington, Missouri, United States

Skin Specialists, PC

Omaha, Nebraska, United States

Juva Skin & Laser Center

New York, New York, United States

Tennessee Clinical Research Center

Nashville, Tennessee, United States

Westlake Dermatology Clinical Research Center

Austin, Texas, United States

Countries

United States

Other Identifiers

LIPO-202-CL-31

Identifier Type: -

Identifier Source: org_study_id